AI
VIVE

Accredited Investors’s VIVEVE MED INC VIVE Stock Holding History

Accredited Investors’s Portfolio VIVE Stock Details VIVE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-33
Closed -$31K – 143
2019
Q1 		$31K Buy
+33
New +$35K 0.01% 137
2018
Q2 		– Sell
-33
Closed -$122K – 130
2018
Q1 		$122K Buy
+33
New +$144K 0.03% 109

Other funds holding VIVE

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Accredited Investors's VIVE Position: Q2 2019 in Review

Accredited Investors sold out of VIVEVE MED INC (VIVE) in Q2 2019, closing a stake of 33 shares — an estimated $31K sold.

Accredited Investors first reported a position in VIVE in Q1 2018 and held it in 2 quarters. The position peaked at $122K in Q1 2018. 30 funds tracked by Wall St. Rank hold VIVE as of Q2 2019.

  • Accredited Investors reported no remaining VIVEVE MED INC position as of Q2 2019 after selling out during the quarter.
  • Accredited Investors sold 33 VIVEVE MED INC shares in Q2 2019, an estimated $31K.
  • Accredited Investors first reported a position in VIVEVE MED INC in Q1 2018 and held it in 2 quarters.
  • Accredited Investors's VIVEVE MED INC position peaked at $122K in Q1 2018.
  • 30 funds tracked by Wall St. Rank held VIVEVE MED INC as of Q2 2019.

Based on Accredited Investors's 13F filing for Q2 2019, filed 13 Aug 2019.